Unfractionated versus fractionated heparin for percutaneous coronary intervention

被引：11

作者：

Arjomand H. ^{[1
]}

Surabhi S.K. ^{[1
]}

Cohen M. ^{[1
]}

机构：

[1] Cardiac Catheterization Laboratory, Mail Stop 119, Hahnemann University Hospital, Philadelphia, PA 19102, Broad and Vine Streets

来源：

Current Cardiology Reports | 2002年 / 4卷 / 4期

关键词：

Percutaneous Coronary Intervention; Enoxaparin; Abciximab; Unfractionated Heparin; Eptifibatide;

D O I：

10.1007/s11886-002-0069-6

中图分类号：

学科分类号：

摘要：

Since the advent of percutaneous coronary intervention (PCI), intravenous unfractionated heparin has been the primary antithrombotic therapy to prevent periprocedural ischemic complications. As compared with unfractionated heparin, low molecular weight heparins (LMWHs) have a greater bioavailability and a more predictable therapeutic response. In several recent studies of patients undergoing PCI, LMWHs have been shown to be as safe and effective as unfractionated heparin; given their better pharmacokinetic profile and the lack of need for coagulation monitoring, they have the potential to replace unfractionated heparin during coronary interventions. This article reviews the current status of anticoagulation therapy with unfractionated heparin and LMWHs in the cardiac catheterization laboratory. Copyright © 2002 by Current Science Inc.

引用

页码：327 / 333

页数：6

共 50 条

[1]

Gruntzig A.R., Senning A., Siegenthaler W.E., Nonoperative dilatation of coronary-artery stenosis. percutaneous transluminal coronary angioplasty, N Engl J Med, 301, pp. 61-68, (1979)

[2]

Popma J.J., Ohman M., Weitz J., Et al., Antithrombotic therapy in patients undergoing percutaneous coronary intervention, Chest, 119, (2001)

[3]

Weitz J.I., Low-molecular-weight heparins, N Engl J Med, 337, pp. 688-698, (1997)

[4]

Cohen M., The role of low-molecular-weight heparin in the management of acute coronary syndromes, Curr Opin Cardiol, 16, pp. 384-389, (2001)

[5]

Montalescot G., Cohen M., Low molecular weight heparins in the cardiac catheterization laboratory, J Thromb Thrombolysis, 7, pp. 319-323, (1999)

[6]

Deutsch E., Cohen M., Radley D.R., Tarazona N., Fromell G.J., Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina, Results of the ESSENCE Trial. Circulation, 98, SUPPL. 1, (1998)

[7]

Collet J.P., Montalescot G., Lison L., Et al., Percutaneous coronary intervention after subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris, Circulation, 1035, pp. 658-663, (2001)

[8]

Collet J.P., Pharmacokinetic study of enoxaparin in patients undergoing percutaneous coronary intervention 8 to 12 hours after subcutaneous injection. The results of the PEPCI trial, The Proceedings of the American Heart Association Meeting, (2001)

[9]

Karsch K.R., Preisack M.B., Baildon R., Et al., Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. results of a randomized, double-blind, unfractionated heparin and placebo-controlled multicenter trial (REDUCE trial), J Am Coll Cardiol, 28, pp. 1437-1443, (1996)

[10]

Rabah M.M., Premmereur J., Graham M., Et al., Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris, Am J Cardiol, 84, pp. 1391-1395, (1999)

← 1 2 3 4 5 →